Opinion: Prasad’s FDA Exit Good for Rare Diseases but New CBER Head Must Repair Eroded Trust

Why It Matters

Leadership instability and opaque regulatory reversals jeopardize investment in rare‑disease drug development and delay life‑saving therapies, affecting both biotech firms and patients.

Key Takeaways

• Vinay Prasad’s departure follows Senate criticism of rare‑disease approvals
• FDA reversed uniQure’s Huntington’s gene‑therapy agreement without documented rationale
• Senator Ron Johnson demands transparency on FDA’s complete response letters
• Draft guidance on plausible‑mechanism therapies signals flexible regulatory approach
• New CBER director must institutionalize advisory committee and surrogate‑endpoint clarity

Pulse Analysis

The rare‑disease community has watched CBER’s revolving door of directors erode confidence in the FDA’s regulatory promise. When sponsors invest billions in clinical programs based on agency guidance, any unexplained shift creates legal risk and delays patient access. The February 26 Senate hearing amplified these concerns, with witnesses citing inconsistent endpoint standards and last‑minute trial redesigns that undermine the predictability essential for biotech financing. Restoring trust now hinges on transparent decision‑making and consistent application of established pathways.

UniQure’s experience with its Huntington’s disease gene therapy illustrates the problem. After a June 2025 written agreement that accepted external natural‑history controls, the FDA abruptly reversed its stance in November, demanding a sham‑surgery‑controlled Phase 3 trial. The agency offered no documented rationale, prompting Senator Ron Johnson to label the request "bureaucratic idiocy" and to push for a congressional investigation. This back‑and‑forth not only stalls a potentially transformative therapy but also signals to investors that FDA commitments can be renegotiated without notice, raising the cost of rare‑disease development.

Looking ahead, the new CBER director must move beyond a simple transition. Implementing a rare‑disease advisory committee, clarifying surrogate‑endpoint guidance, and committing to consistent accelerated‑approval criteria are essential steps. The draft plausible‑mechanism framework and the recent accelerated approval of Rocket Pharmaceuticals’ Kresladi demonstrate that flexibility is possible when the agency balances scientific rigor with patient urgency. Transparent communication about regulatory expectations will enable sponsors to align resources effectively, accelerating the pipeline of therapies for ultra‑rare conditions and restoring the credibility that the rare‑disease ecosystem desperately needs.